The FDA has approved an adjuvant regimen combining pembrolizumab and belzutifan for high-risk clear cell renal cell carcinoma following surgery. Dana-Farber researchers cited in the report supported the regulatory pathway for the pembrolizumab–belzutifan combination, a strategy designed to add checkpoint inhibition plus hypoxia pathway targeting after nephrectomy or partial resection. The approval covers adult patients with clear cell RCC meeting high-risk criteria in the post-surgical setting, establishing a new option intended to reduce recurrence risk. For developers, the approval also signals continued confidence in pairing immunotherapy with HIF-2α inhibition in oncology populations where tumor biology includes hypoxia signaling.